Take Control with InsuPad®
Achieve therapeutic target with less hypoglycemia and less insulin

Consensus Statement

 

Insupad Consensus Statement

 

Insupad is an innovative medical device for diabetes patients using prandial insulin.
 
Based on clinical data and clinical experience Insupad can provide: 1) Better glycemic 
control; 2) Less hypoglycemia; 3) Lower postprandial glucose excursions; and/or 4) 
Lower insulin doses.
 
Insupad may be particularly useful in patients using prandial insulin who have any of the 
following: 1) High prandial insulin requirements; 2) Increased risk of hypoglycemia; 3) 
High postprandial glucose excursions; and/or 4) High glucose variability.
 
Completer roster of the 10 Insuline Scientific Advisory Board members and their 
signatures:
 
Dr. Barry Ginsberg  MD, Ph.D. 
Diabetes Consultants
 
 
Prof.  Dr.  Med. Thomas Haak
Diabetes Klinik Bad Mergentheim 
 
 
Prof. Dr. Lutz Heinemann Phd
Profil Institut fuer Stoffwechselforschung GmbH  
 
 
Prof. David C. Klonoff, MD, FACP
University of California, San Francisco
Diabetes Research Institute,Mills-Peninsula Health Services
 
 
Prof. Itamar Raz, MD
Diabetes Unit, Department of Medicine
Hadassah University Hospital
 
 
Julio Wainstein, MD
The E. wolfsonMedical Center
 
 
Prof. Dr. med. Andreas Pfützner Ph.D.
Geschäftsführer IKFE GmbH
Institut für klinische Forschung und Entwicklung
 
 
William Tamborlane, MD
Department of Pediatrics
Yale University
 
 
Dr. Astrid Tombek 
Diabetes Klinik Bad Mergentheim GmbH 
 
 
Stuart A Weinzimer, MD
Associate Professor of Pediatrics
Yale University School of Medicine
Director, Pediatric Endocrinology Fellowship Program
Medical Director, Type 1 Diabetes Program
 
 
Prof. Lawrence A. Leiter MD FRCPC FACP FAHA
Division of Endocrinology and Metabolism,
St. Michael's Hospital.
Professor of Medicine and Nutritional Sciences,
University of Toronto